Thyroid cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• BRAF 15
• RET 8
• PI3K 0
• TP53 0
• TERT 0
• MAPK 1
• GLP-1 1
• AKT 0
• PTEN 0
• STAT3 0
• mTOR 0
• NTRK 2
• PD-1 5
• ERK 0
• MEK 1
• PSMA 1
• RAS 1
• ALK 1
• EGFR 3
• VEGF 2
• PD-L1 0
• JAK 0
• CTNNB1 0
• KRAS 1
• NRAS 2
• NRF2 0
• PPAR 0
• TROP2 3
• AMPK 0
• DLL3 2
• HIF-1 0
• PIK3CA 0
• ABL1 0
• DPP-4 0
• IL-6 1
• METTL3 0
• TNF 0
• YAP 0
• AXL 1
• EZH2 0
• FGFR 0
• JNK 0
• MET 1
• MYC 0
• PKM2 0
• ROS1 1
• SGLT2 0
• STING 0
• ATM 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CGRP 0
• CTLA-4 0
• CXCR4 0
• FAK 0
• HMGB1 0
• IDH 0
• IDO1 0
• NLRP3 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 26+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

  NCT03975231· City of Hope Medical Center· Updated 15 Oct 2026

  “Accrual goal met”Registry text, quoted unchanged. Source

• Suspended

  JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

  NCT04418167· JS InnoPharm, LLC· Updated 3 Sept 2025

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

  NCT04190628· ABM Therapeutics Corporation· Updated 21 May 2024

  “Not related to safety concerns or lack of efficacy”Registry text, quoted unchanged. Source

• Withdrawn

  Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer

  NCT04739566· Saint Petersburg State University, Russia· Updated 25 Mar 2024

  “Lack of funding”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer

  NCT07886905· Washington University School of Medicine· Source

• Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

  NCT04940052· Novartis Pharmaceuticals· Source

• DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

  NCT07440290· Cancer Research UK· Source

• A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  NCT05503797· Fore Biotherapeutics· Source

• Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

  NCT04238624· Memorial Sloan Kettering Cancer Center· Source

• DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

  NCT05768178· Cancer Research UK· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 24
• Organoids 6
• Mendelian Randomization Analysis 16
• CRISPR-Cas Systems 3
• Gene Expression Profiling 65
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 1
• Exome Sequencing 7
• Proteomics 14
• Metabolomics 9
• Mass Spectrometry 7
• Flow Cytometry 6
• Immunohistochemistry 72
• Liquid Biopsy 9
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 57
• Positron-Emission Tomography 44
• Magnetic Resonance Imaging 18
• Machine Learning 72
• Deep Learning 44
• Cohort Studies 118
• Genome-Wide Association Study 16

• Incorporating natural language processing-derived features from pathology reports into machine learning models to predict differentiated thyroid cancer recurrence.

  Front Endocrinol (Lausanne), Oct 2026

• Network pharmacology and machine learning reveal kit as a target of roburic acid in anaplastic thyroid carcinoma: Preliminary in vitro validation.

  PLoS One, Oct 2026

• A genetic algorithm-optimized EWMA control chart integrating machine learning-based risk prediction for multistage thyroid cancer treatment monitoring.

  PLoS One, Oct 2026

• An explainable and leakage-aware machine learning model for early risk stratification of radioiodine-refractory differentiated thyroid cancer: development and single-center geographic external validation.

  Front Endocrinol (Lausanne), Oct 2026

• Machine learning-based prediction of lymph node metastasis in papillary thyroid carcinoma: an interpretable multidimensional model.

  Front Endocrinol (Lausanne), Sept 2026

• Machine learning diagnostic model integrating ultrasound features and immune-inflammatory biomarkers for identifying papillary thyroid carcinoma in patients with Hashimoto's thyroiditis.

  Front Immunol, Sept 2026

• The value of machine learning models in predicting lung metastasis in papillary thyroid carcinoma.

  Front Endocrinol (Lausanne), Sept 2026

• Quantitative Super-Resolution Ultrasound Microvascular Features for Machine Learning-Based Classification of Thyroid Nodules.

  J Vis Exp, Sept 2026

• Interpretable four-class machine learning prediction of initial I-131 therapy responses in differentiated thyroid cancer.

  Ann Med, Sept 2026

• Predicting unfavorable response to initial radioactive iodine therapy in differentiated thyroid cancer: an explainable machine learning and survival analysis approach.

  Front Endocrinol (Lausanne), Sept 2026

See which targets of this disease your abstract mentions, and go to the people working on them.